http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 22 May 2026 06:08:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+22/26538194.html si-local-file:///var/storage/secattach/20260522/26538194.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+22/26538194.html Fri, 22 May 2026 06:08:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+22/26538194.html si-local-file:///var/storage/secattach/20260522/26538194.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+22/26538194.html Fri, 22 May 2026 06:08:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+22/26538194.html si-local-file:///var/storage/secattach/20260522/26538194.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+22/26538194.html Fri, 22 May 2026 06:08:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+21/26531079.html si-local-file:///var/storage/secattach/20260521/26531079.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+21/26531079.html Thu, 21 May 2026 06:30:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+21/26531079.html si-local-file:///var/storage/secattach/20260521/26531079.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+21/26531079.html Thu, 21 May 2026 06:30:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+21/26531079.html si-local-file:///var/storage/secattach/20260521/26531079.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+21/26531079.html Thu, 21 May 2026 06:30:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Cheng+Chig+Fung/26530994.html si-local-file:///var/storage/secattach/20260521/26530994.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Cheng+Chig+Fung/26530994.html Thu, 21 May 2026 06:17:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Cheng+Chig+Fung/26530994.html si-local-file:///var/storage/secattach/20260521/26530994.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Cheng+Chig+Fung/26530994.html Thu, 21 May 2026 06:17:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Cheng+Chig+Fung/26530994.html si-local-file:///var/storage/secattach/20260521/26530994.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Cheng+Chig+Fung/26530994.html Thu, 21 May 2026 06:17:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Nixon+Charles+George+Rupert/26530977.html si-local-file:///var/storage/secattach/20260521/26530977.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Nixon+Charles+George+Rupert/26530977.html Thu, 21 May 2026 06:11:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Nixon+Charles+George+Rupert/26530977.html si-local-file:///var/storage/secattach/20260521/26530977.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Nixon+Charles+George+Rupert/26530977.html Thu, 21 May 2026 06:11:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Nixon+Charles+George+Rupert/26530977.html si-local-file:///var/storage/secattach/20260521/26530977.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Nixon+Charles+George+Rupert/26530977.html Thu, 21 May 2026 06:11:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Su+Wei-guo/26530949.html si-local-file:///var/storage/secattach/20260521/26530949.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Su+Wei-guo/26530949.html Thu, 21 May 2026 06:07:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Su+Wei-guo/26530949.html si-local-file:///var/storage/secattach/20260521/26530949.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Su+Wei-guo/26530949.html Thu, 21 May 2026 06:07:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Su+Wei-guo/26530949.html si-local-file:///var/storage/secattach/20260521/26530949.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Su+Wei-guo/26530949.html Thu, 21 May 2026 06:07:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Chiu+Lorenso/26530916.html si-local-file:///var/storage/secattach/20260521/26530916.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Chiu+Lorenso/26530916.html Thu, 21 May 2026 06:04:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Chiu+Lorenso/26530916.html si-local-file:///var/storage/secattach/20260521/26530916.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Chiu+Lorenso/26530916.html Thu, 21 May 2026 06:04:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Chiu+Lorenso/26530916.html si-local-file:///var/storage/secattach/20260521/26530916.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HUTCHMED+%28China%29+Ltd++++++For%3A+May+20++Filed+by%3A+Chiu+Lorenso/26530916.html Thu, 21 May 2026 06:04:00 -0400 HCM HCM O.07132798 http://www.streetinsider.com/Corporate+News/China+approves+Innovent+and+HUTCHMED+drug+combo+for+kidney+cancer/26530811.html <p>China's National Medical Products Administration has approved a combination therapy from Innovent Biologics Inc. and HUTCHMED (NASDAQ: HCM) for treating patients with locally advanced or metastatic renal cell carcinoma.</p><p>The approval covers the combination of TYVYT (sintilimab injection) and ELUNATE (fruquintinib) for patients who have failed prior vascular endothelial growth factor receptor-tyrosine kinase inhibitors therapy and have not received PD-1 or PD-L1 inhibitor therapy in the first-line setting.</p><p>The decision was based on data from the FRUSICA-2 registration study, a randomized, open-label trial that evaluated the combination against axitinib or everolimus monotherapy for second-line treatment. The study met its primary endpoint of http://www.streetinsider.com/Corporate+News/China+approves+Innovent+and+HUTCHMED+drug+combo+for+kidney+cancer/26530811.html Thu, 21 May 2026 06:02:17 -0400 HCM http://www.streetinsider.com/FDA/China+approves+Innovent+and+HUTCHMED+drug+combo+for+kidney+cancer/26530811.html <p>China's National Medical Products Administration has approved a combination therapy from Innovent Biologics Inc. and HUTCHMED (NASDAQ: HCM) for treating patients with locally advanced or metastatic renal cell carcinoma.</p><p>The approval covers the combination of TYVYT (sintilimab injection) and ELUNATE (fruquintinib) for patients who have failed prior vascular endothelial growth factor receptor-tyrosine kinase inhibitors therapy and have not received PD-1 or PD-L1 inhibitor therapy in the first-line setting.</p><p>The decision was based on data from the FRUSICA-2 registration study, a randomized, open-label trial that evaluated the combination against axitinib or everolimus monotherapy for second-line treatment. The study met its primary endpoint of http://www.streetinsider.com/FDA/China+approves+Innovent+and+HUTCHMED+drug+combo+for+kidney+cancer/26530811.html Thu, 21 May 2026 06:02:17 -0400 HCM http://www.streetinsider.com/Press+Releases/Innovent+and+HUTCHMED+Jointly+Announce+NMPA+Approval+for+TYVYT%C2%AE+%28Sintilimab+Injection%29+in+Combination+with+ELUNATE%C2%AE+%28Fruquintinib%29+for+the+Treatment+of+Patients+with+Locally+Advanced+or+Metastatic+R/26530683.html <div class="xn-content"> <ul type="disc"><li><i>Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>May 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases,  and <span value="NASDAQ-NMS:HCM" idsrc="xmltag.org" >HUTCHMED (China) Limited</span> ("<a target="_blank" href="https://www.hutch-med.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:HCM" idsrc="xmltag.org" >HUTCHMED</span></a>") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the New Drug Application (NDA) for the combination http://www.streetinsider.com/Press+Releases/Innovent+and+HUTCHMED+Jointly+Announce+NMPA+Approval+for+TYVYT%C2%AE+%28Sintilimab+Injection%29+in+Combination+with+ELUNATE%C2%AE+%28Fruquintinib%29+for+the+Treatment+of+Patients+with+Locally+Advanced+or+Metastatic+R/26530683.html Thu, 21 May 2026 06:00:00 -0400 01801 13 1801 6IB A.33615634 HCM HCM IVBIY O.07116439 O.07132798 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+and+HUTCHMED+Jointly+Announce+NMPA+Approval+for+TYVYT%C2%AE+%28Sintilimab+Injection%29+in+Combination+with+ELUNATE%C2%AE+%28Fruquintinib%29+for+the+Treatment+of+Patients+with+Locally+Advanced+or+Metastatic+R/26530683.html <div class="xn-content"> <ul type="disc"><li><i>Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>May 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases,  and <span value="NASDAQ-NMS:HCM" idsrc="xmltag.org" >HUTCHMED (China) Limited</span> ("<a target="_blank" href="https://www.hutch-med.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:HCM" idsrc="xmltag.org" >HUTCHMED</span></a>") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the New Drug Application (NDA) for the combination http://www.streetinsider.com/Press+Releases/Innovent+and+HUTCHMED+Jointly+Announce+NMPA+Approval+for+TYVYT%C2%AE+%28Sintilimab+Injection%29+in+Combination+with+ELUNATE%C2%AE+%28Fruquintinib%29+for+the+Treatment+of+Patients+with+Locally+Advanced+or+Metastatic+R/26530683.html Thu, 21 May 2026 06:00:00 -0400 01801 13 1801 6IB A.33615634 HCM HCM IVBIY O.07116439 O.07132798 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+and+HUTCHMED+Jointly+Announce+NMPA+Approval+for+TYVYT%C2%AE+%28Sintilimab+Injection%29+in+Combination+with+ELUNATE%C2%AE+%28Fruquintinib%29+for+the+Treatment+of+Patients+with+Locally+Advanced+or+Metastatic+R/26530683.html <div class="xn-content"> <ul type="disc"><li><i>Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>May 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases,  and <span value="NASDAQ-NMS:HCM" idsrc="xmltag.org" >HUTCHMED (China) Limited</span> ("<a target="_blank" href="https://www.hutch-med.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:HCM" idsrc="xmltag.org" >HUTCHMED</span></a>") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the New Drug Application (NDA) for the combination http://www.streetinsider.com/Press+Releases/Innovent+and+HUTCHMED+Jointly+Announce+NMPA+Approval+for+TYVYT%C2%AE+%28Sintilimab+Injection%29+in+Combination+with+ELUNATE%C2%AE+%28Fruquintinib%29+for+the+Treatment+of+Patients+with+Locally+Advanced+or+Metastatic+R/26530683.html Thu, 21 May 2026 06:00:00 -0400 01801 13 1801 6IB A.33615634 HCM HCM IVBIY O.07116439 O.07132798 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+and+HUTCHMED+Jointly+Announce+NMPA+Approval+for+TYVYT%C2%AE+%28Sintilimab+Injection%29+in+Combination+with+ELUNATE%C2%AE+%28Fruquintinib%29+for+the+Treatment+of+Patients+with+Locally+Advanced+or+Metastatic+R/26530683.html <div class="xn-content"> <ul type="disc"><li><i>Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>May 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases,  and <span value="NASDAQ-NMS:HCM" idsrc="xmltag.org" >HUTCHMED (China) Limited</span> ("<a target="_blank" href="https://www.hutch-med.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:HCM" idsrc="xmltag.org" >HUTCHMED</span></a>") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the New Drug Application (NDA) for the combination http://www.streetinsider.com/Press+Releases/Innovent+and+HUTCHMED+Jointly+Announce+NMPA+Approval+for+TYVYT%C2%AE+%28Sintilimab+Injection%29+in+Combination+with+ELUNATE%C2%AE+%28Fruquintinib%29+for+the+Treatment+of+Patients+with+Locally+Advanced+or+Metastatic+R/26530683.html Thu, 21 May 2026 06:00:00 -0400 01801 13 1801 6IB A.33615634 HCM HCM IVBIY O.07116439 O.07132798 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+and+HUTCHMED+Jointly+Announce+NMPA+Approval+for+TYVYT%C2%AE+%28Sintilimab+Injection%29+in+Combination+with+ELUNATE%C2%AE+%28Fruquintinib%29+for+the+Treatment+of+Patients+with+Locally+Advanced+or+Metastatic+R/26530683.html <div class="xn-content"> <ul type="disc"><li><i>Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>May 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases,  and <span value="NASDAQ-NMS:HCM" idsrc="xmltag.org" >HUTCHMED (China) Limited</span> ("<a target="_blank" href="https://www.hutch-med.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:HCM" idsrc="xmltag.org" >HUTCHMED</span></a>") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the New Drug Application (NDA) for the combination http://www.streetinsider.com/Press+Releases/Innovent+and+HUTCHMED+Jointly+Announce+NMPA+Approval+for+TYVYT%C2%AE+%28Sintilimab+Injection%29+in+Combination+with+ELUNATE%C2%AE+%28Fruquintinib%29+for+the+Treatment+of+Patients+with+Locally+Advanced+or+Metastatic+R/26530683.html Thu, 21 May 2026 06:00:00 -0400 01801 13 1801 6IB A.33615634 HCM HCM IVBIY O.07116439 O.07132798 O.39140405